BridgeBio launches rare genetic disorder subsidiary

BridgeBio Pharma LLC (Palo Alto, Calif.) launched another subsidiary, forming CoA Therapeutics Inc. to develop small molecules which increase coenzyme A levels to treat rare genetic disorders.

CoA CEO Shafique Virani told BioCentury that the compounds directly target pantothenate kinase 1 (PANK1) and PANK3 to up-regulate coenzyme A. The candidates were in-licensed from St. Jude Children's Research Hospital (Memphis, Tenn.). ...